Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

BACKGROUND: Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Emens, Leisha A, Molinero, Luciana, Loi, Sherene, Rugo, Hope S, Schneeweiss, Andreas, Diéras, Véronique, Iwata, Hiroji, Barrios, Carlos H, Nechaeva, Marina, Nguyen-Duc, Anh, Chui, Stephen Y, Husain, Amreen, Winer, Eric P, Adams, Sylvia, Schmid, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328980/
https://www.ncbi.nlm.nih.gov/pubmed/33523233
http://dx.doi.org/10.1093/jnci/djab004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328980/
https://www.ncbi.nlm.nih.gov/pubmed/33523233
http://dx.doi.org/10.1093/jnci/djab004

Ejemplares similares